The sentinel node invasion level (SNIL) as a prognostic parameter in melanoma
Lutz Kretschmer1, Christina Mitteldorf2, Simin Hellriegel2
1Department of Dermatology, Venereology and Allergology, University Medical Center, Göttingen, Germany. lkre@med.uni-goettingen.de.
Summary
Sentinel lymph node tumor burden is crucial for melanoma staging. A new Sentinel Lymph Node Invasion Level (SNIL) system accurately predicts patient survival and recurrence risk, guiding adjuvant therapy decisions.
Area of Science:
- Oncology
- Pathology
- Surgical Oncology
Background:
- Sentinel lymph node (SN) tumor burden is increasingly vital for melanoma staging and may be incorporated into future N classifications.
- Accurate assessment of SN metastasis is critical for determining prognosis and guiding treatment decisions in melanoma patients.
Purpose of the Study:
- To investigate the prognostic significance of melanoma infiltration patterns within anatomically defined lymph node substructures.
- To develop and validate a Sentinel Lymph Node Invasion Level (SNIL) system for stratifying melanoma patient outcomes.
Main Methods:
- Retrospective cohort study of 1250 patients with SN biopsy for melanoma.
- Detailed pathological analysis of SN substructure infiltration (lymph vessels, sinuses, cortex, paracortex, medulla, capsule).
- Classification of 338 SN-positive patients into three SNIL groups based on invasion patterns; survival analysis using Kaplan-Meier and Cox models.
Main Results:
- The SNIL system significantly stratified SN-positive patients into distinct groups based on recurrence-free survival (RFS), melanoma-specific survival (MSS), and nodal basin recurrence.
- Patients with SNIL 1 (minimal invasion) had MSS similar to SN-negative patients.
- Advanced invasion into the medulla or capsule (SNIL 3) indicated a poor prognosis, with significantly higher recurrence rates and lower MSS.
Conclusions:
- The SNIL system provides valuable prognostic information beyond simple SN metastasis detection.
- SNIL effectively stratifies melanoma patients based on the extent of lymph node involvement, aiding in risk assessment.
- This classification may optimize the selection of adjuvant therapies by better defining the benefit-risk ratio for individual patients.


